This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).
Uterine Serous Carcinoma
This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
-
Alaska Women's Cancer Care, Anchorage, Alaska, United States, 99508
Honor Health, Phoenix, Arizona, United States, 85016
Arizona Oncology Associates Wilmot HOPE, Tucson, Arizona, United States, 85711
University of California Irvine Medical Center, Orange, California, United States, 92868
University of California San Francisco at Mission Bay, San Francisco, California, United States, 94158
Mount Sinai Medical Center, Miami Beach, Florida, United States, 33140
Sarasota Memorial Hospital, Sarasota, Florida, United States, 34239
University of South Florida, Tampa, Florida, United States, 33606
Northside Hospital, Atlanta, Georgia, United States, 30342
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States, 30912
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
FEMALE
No
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc,
Project Director, STUDY_DIRECTOR, K-Group Beta (A wholly owned subsidiary of Zentalis Pharmaceuticals)
2025-05-31